In Australia, drugs and poisons are grouped together in Schedules listed in the Poisons Standard that require similar regulatory controls over their availability, according to government.
SCHEDULE 3
CANNABIDIOL in oral, oromucosal and sublingual preparations included in the Australian Register of Therapeutic Goods when:
a) the cannabidiol is either plant derived or, when synthetic, only contains the (-)-CBD enantiomer; and
b) the cannabidiol comprises 98% or more of the total cannabinoid content of the preparation; and
c) any cannabinoids, other than cannabidiol, must be only those naturally found in cannabis and comprise 2% or less of the total cannabinoid content of the preparation and of which tetrahydrocannabinol (THC) can only comprise 1% of the total cannabinoid content; and
d) the maximum recommended daily dose is 150 mg or less of cannabidiol; and
e) packed in blister or strip packaging or in a container fitted with a child-resistant closure; and
f) in packs containing not more than 30 days’ supply; and
g) for persons aged 18 years and over.
SCHEDULE 4
CANNABIDIOL in preparations for therapeutic use or analytical and scientific research where:
a) cannabidiol comprises 98% or more of the total cannabinoid content of the preparation; and
b) any cannabinoids, other than cannabidiol, must be only those naturally found in cannabis and comprise 2% or less of the total cannabinoid content of the preparation;
except when:
i) included in Schedule 3; or
ii) in hemp seed oil at a concentration of 75 mg/kg or less.
SCHEDULE 8
# CANNABIS (including seeds, extracts, resins and the plant, and any part of the plant) when prepared or packed for human therapeutic use, when:
- a) cultivated or produced, or in products manufactured[1], in accordance with the Narcotic Drugs Act 1967; and/or
- b) for use in products manufactured in accordance with the Narcotic Drugs Act 1967; and/or
- c) imported as therapeutic goods, or for use in therapeutic goods, for supply, in accordance with the Therapeutic Goods Act 1989; and/or
- d) in therapeutic goods supplied in accordance with the Therapeutic Goods Act 1989,
except:
- i) when it is in a product to which item 4, 8, 10, 11 or 12 of Schedule 5A to the Therapeutic Goods Regulations 1990 applies; or
- ii) when separately specified in the NABIXIMOLS entry in this Schedule; or
iii) when captured by the CANNABIDIOL entry in Schedule 4 or Schedule 3; or
- iv) hemp seed oil containing 75 mg/kg or less of cannabidiol and 10 mg/kg or less of tetrahydrocannabinols.
# DRONABINOL (delta-9-tetrahydrocannabinol) when prepared and packed for therapeutic use.
# NABIXIMOLS (botanical extract of Cannabis sativa which includes the following cannabinoids: tetrahydrocannabinols, cannabidiol, cannabinol, cannabigerol, cannabichromene, cannabidiolic acid, tetrahydrocannabinolic acids, tetrahydrocannabivarol, and cannabidivarol, where tetrahydrocannabinols and cannabidiol (in approximately equal proportions) comprise not less than 90% of the total cannabinoid content) in a buccal spray for human therapeutic use.
# TETRAHYDROCANNABINOLS when extracted from cannabis for human therapeutic use, when:
- a)included in products manufactured in accordance with the Narcotic Drugs Act 1967; and/or
- b)imported as therapeutic goods, or for use in therapeutic goods, for supply, in accordance with the Therapeutic Goods Act 1989; and/or
- c)in therapeutic goods supplied in accordance with the Therapeutic Goods Act 1989,
except when:
- i)it is in a product to which item 4, 8, 10, 11 or 12 of Schedule 5A to the Therapeutic Goods Regulations 1990 applies; or
- ii)separately specified in the NABIXIMOLS entry in this Schedule; or
iii) captured by the CANNABIDIOL entry in Schedule 4 or Schedule 3; or
- iv)in hemp seed oil at a concentration of 10 mg/kg or less.
SCHEDULE 9
CANNABIS (including seeds, extracts, resins, and the plant and any part of the plant when packed or prepared), except:
- a) when separately specified in these Schedules; or
- b) processed hemp fibre containing 0.1% or less of tetrahydrocannabinols and hemp fibre products manufactured from such fibre; or
- c) hemp seed oil containing 75 mg/kg or less of cannabidiol and 10 mg/kg or less of tetrahydrocannabinols.
SYNTHETIC CANNABINOMIMETICS except when separately specified in these Schedules.
TETRAHYDROCANNABINOLS and their alkyl homologues, except:
- a)when included in Schedule 4 or Schedule 8; or
- b)processed hemp fibre containing 0.1% or less of tetrahydrocannabinols, and hemp fibre products manufactured from such fibre; or
- c)in hemp seed oil at a concentration of 10 mg/kg or less.
[1] “Cultivation”, “production” and “manufacture” have the same meaning as in the Narcotic Drugs Act 1967.